Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson Sells 3,678 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Molly Henderson sold 3,678 shares of the company’s stock in a transaction on Monday, April 7th. The shares were sold at an average price of $4.55, for a total value of $16,734.90. Following the completion of the transaction, the chief financial officer now directly owns 89,868 shares in the company, valued at approximately $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Molly Henderson also recently made the following trade(s):

• On Tuesday, January 21st, Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $6.59, for a total transaction of $43,381.97.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT opened at $4.11 on Friday. Phathom Pharmaceuticals, Inc. has a 52-week low of $3.81 and a 52-week high of $19.71. The firm has a market cap of $286.21 million, a price-to-earnings ratio of -0.72 and a beta of 0.35. The business’s fifty day moving average is $5.47 and its 200-day moving average is $9.16.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a report on Wednesday. Craig Hallum reiterated a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. The Goldman Sachs Group cut their target price on Phathom Pharmaceuticals from $18.00 to $12.00 and set a “neutral” rating for the company in a research report on Monday, March 10th. Finally, Cantor Fitzgerald upgraded Phathom Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Phathom Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $22.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PHAT. Jennison Associates LLC boosted its stake in shares of Phathom Pharmaceuticals by 20.4% in the 4th quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock valued at $57,348,000 after purchasing an additional 1,196,118 shares in the last quarter. Vanguard Group Inc. lifted its stake in Phathom Pharmaceuticals by 3.1% in the 4th quarter. Vanguard Group Inc. now owns 2,779,561 shares of the company’s stock valued at $22,570,000 after purchasing an additional 83,238 shares during the last quarter. Wasatch Advisors LP boosted its position in Phathom Pharmaceuticals by 531.3% in the fourth quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company’s stock valued at $12,658,000 after buying an additional 1,311,986 shares in the last quarter. FMR LLC boosted its position in Phathom Pharmaceuticals by 49,000.7% in the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock valued at $23,578,000 after buying an additional 1,301,458 shares in the last quarter. Finally, Catalys Pacific LLC grew its stake in shares of Phathom Pharmaceuticals by 4.0% during the fourth quarter. Catalys Pacific LLC now owns 1,167,114 shares of the company’s stock worth $9,477,000 after buying an additional 44,542 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.